{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"None"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Mild"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Moderate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Severe"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Very Severe"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"The frequency of tinnitus will be measured by participants' worst level response at any time point on the PRO-CTCAE® question \"In the last 7 days, what was the severity of ringing in your ears at its worst?\". Item responses were categorized as 'None', 'Mild', 'Moderate', 'Severe', and 'Very Severe'.","groups":[{"description":"Participants undergo standard of care radiation therapy daily in combination with cisplatin on day 1. Between 4-5 hours after each cisplatin infusion, patients also receive sodium thiosulfate over 1-2 hours on day 1. Treatment will continue on either a 1 week or 3 week cycle per physician discretion for up to 6-7 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Cisplatin, Radiotherapy, STS"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 18 weeks","title":"Number of Participants Reporting Tinnitus by Severity","type":"SECONDARY","unitOfMeasure":"participants"}